Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Therapeutic Substance(s): 

Anticancer Drugs. 2008 Jan;19(1):91-6.

Continuous
oral capecitabine at fixed dose in patients older than 75 years with
metastatic colorectal and gastric cancer: a study of the
Multidisciplinary Oncology Group on Gastrointestinal Tumors.

 
Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G; Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Department Human Pathology and Oncology, University of Siena, Siena, Italy.

The
aim of this study was to investigate the safety profile of continuous
oral capecitabine at fixed dose in patients older than 75 years, having
metastatic colorectal and gastric cancer. Capecitabine was administered
at a fixed dose of 2000 mg daily without interruptions. Thirty-four
patients were considered evaluable for toxicity and efficacy. The
median age was 81 years (range 76-85). The median duration of treatment
was 113 days (range 24-238 days). No grade 4 toxicity was observed. One
patient had grade 3 nausea and vomiting, and one had grade 3 diarrhea.
Partial responses were observed in six patients with colorectal cancer,
and in one patient with gastric cancer. This study suggests that
continuous oral capecitabine at a fixed daily dose of 2000 mg is well
tolerated, and that it allows for the simplification and ease of dosing
in elderly patients with metastatic colorectal and gastric cancer.